A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

This study tests a new cancer drug called BL-M14D1 — an antibody-drug conjugate that delivers chemotherapy directly to cancer cells — in patients with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no remaining standard treatment options. **You may be eligible if...** - You are 18–75 years old (or 18 and older for later study stages) - You have confirmed advanced or metastatic cancer with no effective standard treatment remaining - You are in good general health (ECOG 0 or 1) - Your organs (heart, liver, kidneys, blood) are functioning well enough to receive treatment - You are not pregnant and willing to use contraception **You may NOT be eligible if...** - You have had recent cancer treatment (within 4–6 weeks) - You have severe heart disease or poor cardiac function - You have active brain metastases that are symptomatic - You are pregnant or breastfeeding - You have uncontrolled infections or serious medical conditions Talk to your doctor to see if this trial is right for you.